Head and neck cancer is the sixth most common cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for about 2% of all cancers and 1.9% of cancer-related deaths globally. OSCC is characterized by local invasiveness and lymph node metastatic ability, making it a very malignant cancer.
Glioblastoma is the most common and aggressive malignant brain tumor in adults. Although microtubule-targeting agents (MTAs) are among the most widely used first-line therapies in cancer, their efficacy in glioblastoma is limited by poor penetration of the blood–brain barrier.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits observed with next-generation targeted therapies in ALK- and ROS1-rearranged NSCLC. Given the molecular heterogeneity of EGFR-mutant NSCLC, which includes over 100 distinct mutations, there is a continued need for more effective and mutation-specific therapeutic strategies.
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Galapagos NV has divulged probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
The mitochondria play a crucial multifunctional role in the progression of malignant tumors. Therefore, researchers are working to understand the link between mitochondrial DNA mutations and abnormalities in mitochondrial-associated proteins and cancer development and progression.
Erasca Inc. has obtained IND clearance by the FDA for ERAS-4001, an oral selective pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant solid tumors.
Radiopharm Theranostics Ltd. has reported preclinical data from studies with the Lu177-B7H3-monoclonal antibody (mAb) RV-01 demonstrating favorable biodistribution and showing that RV-01 maintained high tumor uptake.
LIN28 is a family of RNA-binding proteins that regulate stem cell biology and pluripotency and are involved in oncogenesis through the interaction with tumor suppressor microRNA let-7. The expression of LIN28 leads to the loss of function of let-7, leading to tumorigenesis, and has been tied to tumor aggressiveness and poor survival in children with brain tumors.
The systemic virotherapy strategy involves not only the direct delivery of therapeutic payloads encoded by viruses to tumors, but also the modification of the tumor microenvironment, aiming to target both primary and metastatic lesions. At the ongoing American Society of Clinical Oncology (ASCO) meeting, researchers from Calidi Biotherapeutics Inc. reported the development of a novel approach using a selected and engineered tumor-selective strain of vaccinia virus.
RSS
